Founded in 1997, Ergomed plc is dedicated to the provision of specialised services to the pharmaceutical industry and the development of new drugs. Operating with a global footprint in over 100 countries, Ergomed enables our clients to access solutions even for their toughest clinical development and trial management challenges from early phase to complex late stage programmes. Ergomed has provided and managed clinical development, trial management and pharmacovigilance services for over 300 clients: these range from top 10 pharmaceutical and generics organizations to small and mid-sized drug development companies.

Global Coverage

As a global CRO, Ergomed has a worldwide network designed to specifically match the requirements of today’s complex development programs. Our global reach allows us to support the development and writing of protocols, fulfill the regulatory requirements, and then to identify, enroll and process patients who are the best fit for the study. Our experienced team is here to support your program from start to finish, ensuring that your study remains on time and on budget.


Following is a chart of history of the Ergomed plc group of companies:


Ergomed founding

Ergomed was founded in Zagreb, Croatia by Dr Miroslav Reljanovic, who was a clinical investigator in numerous Phase II and III studies in the field of neurology.


First Co-Development Deal

Dr Reljanovic, successfully introduced an innovative co-development business model to support the development of products in the European region.


PrimeVigilance formed

PrimeVigilance was formed by co-founders Elliot Brown, MB, MRCGP, FFPM, a well-known international expert in drug safety, and Dr Reljanovic.  PrimeVigilance became, and remains, a leading specialist vendor of contracted pharmacovigilance services to the pharmaceutical industry.


Ergomed PLC IPO

Ergomed was successfully added to the AIM market of the London Stock Exchange and trades under the symbol ERGO.


Sound Opinion

Sound Opinion, a Medical Information Service company, was acquired to bolster the PrimeVigilance offering.



Ergomed acquired Nottingham based Haemostatix to access its proprietary technology and pipeline of two lead products, PeproStat™ and ReadyFlow™.



The acquisitions of German-based O+P and GASD, respectively CRO and biostatistics companies was completed to bolster Ergomed’s full-service offering



A leading pharmacovigilance and regulatory services business PharmInvent was acquired in 2016



In 2017, Ergomed acquired PSR Group BV, a specialist Orphan Drug CRO, to further enhance expertise in rare disease speciality

Ashfield PV

In January 2020: Ergomed announced the acquisition of Ashfield Pharmacovigilance Inc. (“Ashfield PV”), a specialist pharmacovigilance services provider based in Cary in the Research Triangle, North Carolina, USA


In December 2020, Ergomed acquired MedSource, an award winning oncology focused US based CRO.


After completing an IPO in 2014, Ergomed plc is a publicly traded company on the AIM London Stock Exchange, using the symbol ERGO.

Learn more